Tools
Alagille Syndrome
Introduction
Alagille syndrome (ALGS) is an autosomal-dominant multisystem disorder caused by pathogenic variants in the JAG1 or NOTCH2 genes that disrupt the Notch signalling pathway, which is critical for embryonic development.[1][2] The syndrome occurs in approximately 1 in 30,000 to 50,000 live births, though this may underestimate true prevalence due to variable expressivity and reduced penetrance.[3][4] The hallmark feature is the paucity of interlobular bile ducts, leading to chronic cholestasis. This typically presents in the first 3 months of life with jaundice, pruritus, and elevated gamma-glutamyltransferase levels.
Beyond the liver, ALGS affects multiple organ systems with characteristic features including cardiac abnormalities, distinctive facial features, skeletal anomalies, ophthalmologic findings, and renal involvement. Disease severity varies dramatically even within families, ranging from asymptomatic or isolated features to severe multiorgan disease that requires intervention.[3] While some infants with significant cholestasis may experience well-compensated liver disease later in life, an estimated 20% to 30% of patients require liver transplantation for complications, including intractable pruritus, severe growth failure, liver synthetic dysfunction, portal hypertension, or severe osteodystrophy.[5]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Alagille syndrome is inherited in an autosomal dominant manner with variable penetrance. In 1997, pathogenic mutations in JAG1, which encodes a ligand in the Notch signaling pathway, were first identified. Pathogenic variants in JAG1 on chromosome 20p12 account for approximately 90% to 95% of individuals with ALGS, including 89% due to sequence variants and 5% to 7% due to partial or complete gene deletions.[6] Mutations in NOTCH2, located on chromosome 1p11-p12 and encoding a receptor within the same pathway, account for approximately 5% of cases. Data from the Global Alagille Alliance study identified NOTCH2 variants in 34 of 952 patients (3.6%)[7][8]. A 2019 comprehensive review cataloged 713 total variants across both genes, and a 2025 study identified 30 NOTCH2 variants.[9][7]
JAG1 and NOTCH2 are both transmembrane proteins whose interaction triggers proteolytic cleavage of NOTCH2, releasing an intracellular fragment that translocates to the nucleus to regulate target gene expression, including members of the HES and HEY families. JAG1 is the ligand, while NOTCH2 is the receptor. Both are single-pass transmembrane proteins, but they have distinct roles in the signaling cascade. The basis for variable presentation and severity remains incompletely understood, though not entirely unknown. Although pathogenic variants are well defined, genotype-phenotype correlation studies have consistently failed to show associations between mutation type and clinical manifestations or severity.[2]
Several mechanisms likely contribute to phenotypic variability:
Epidemiology
ALGS affects males and females equally, with no known sex predilection. The estimated incidence is 1 in 30,000 to 50,000 live births in the United States and worldwide, with no known racial or ethnic predilection.[6][11][12] The syndrome is likely underdiagnosed due to its variable phenotype and reduced penetrance. Advances in genetic testing have improved detection rates, but many cases may still go unrecognized.
Age of presentation typically occurs in infancy or early childhood, with most patients presenting with neonatal cholestasis. In the multicenter cohort, 92.6% had a history of neonatal cholestasis.[13] Clinical manifestations can vary by age. Characteristic facial features may be difficult to recognize in the neonatal period but become more apparent with age.[14] Pruritus, when present, typically manifests during the first 10 years of life and affects 59% to 88% of patients.[15]
History and Physical
The expected history in ALGS typically begins with neonatal cholestasis, manifesting as jaundice, pruritus, and acholic stools within the first 3 months of life.[14] However, presentation varies widely, with some patients presenting with isolated cardiac defects or subclinical manifestations that may not be recognized until later in childhood or adulthood.[16] Key clinical features include congenital heart disease, characteristic facial features, skeletal anomalies, and ocular findings, with renal and vascular involvement increasingly recognized. Marked phenotypic variability is a defining feature and complicates diagnosis and management.
Hepatic Manifestations
Hepatic findings are the most common presenting feature and the hallmark of AGLS. They typically present in infancy with direct hyperbilirubinemia and demonstrate variable disease progression. While some children improve during early childhood, others develop progressive liver disease. Severe cholestasis in young children (total bilirubin >6.5 mg/dL, conjugated bilirubin >4.5 mg/dL, and cholesterol >520 mg/dL) predicts persistent and more severe hepatic involvement. Advanced cholestatic liver disease can lead to significant complications, including pruritus, xanthomas, fat-soluble vitamin deficiencies, malnutrition, and progression to cirrhosis with portal hypertension.[17]
The histologic hallmark of ALGS is bile duct paucity, defined as a bile duct-to-portal tract ratio less than 0.5 (normal 0.9–1.8); however, this finding may not be evident before 6 months of age.[18] In early infancy, the histologic picture can be confusing and may mimic biliary atresia. During the newborn period, liver biopsies may show a normal ratio of portal tracts to bile ducts, bile duct proliferation, or features suggestive of neonatal hepatitis rather than the characteristic paucity.[2][19]
Cardiovascular Defects
Cardiovascular involvement is common, affecting 90% to 97% of patients with ALGS.[2] Pulmonary vascular involvement is reported in up to 94% of patients. Cardiovascular anomalies were identified by imaging in 75% of patients, with an additional having a peripheral pulmonary stenosis murmur but normal or no imaging.[20] The most common abnormality is stenosis or hypoplasia of the branch pulmonary arteries, documented in approximately 76% of subjects.[20] Tetralogy of Fallot is the most frequent complex congenital disability, affecting 7% to 16% of individuals. Less common abnormalities include ventricular septal defect, atrial septal defect, aortic stenosis, and coarctation of the aorta.[20][21] Additional cardiovascular manifestations include other arterial narrowing affecting the renal arteries, middle aorta syndrome, and cerebrovascular disease (Moyamoya, basilar, and middle cerebral arteries).[22]
Renal Abnormalities
Renal abnormalities can serve as a defining feature of ALGS.[23] Kidney involvement has been reported in approximately 39% of patients, most commonly manifesting as renal dysplasia (58.9%) and less frequently as renal tubular acidosis (9.5%).[24] Although renal insufficiency may be uncommon in children with ALGS, it has been reported in those who have end-stage liver disease. The syndrome can occur and be exacerbated following liver transplantation. The presence of renal disease does not preclude liver transplantation; however, identifying renal involvement is crucial to guide the transplant team in medication selection and minimize exposure to nephrotoxic agents.[25]
The spectrum of renal involvement is broad and includes:
- Renal dysplasia (most common)
- Small hyperechoic kidneys
- Renal cysts
- Uteropelvic obstruction
- Renal tubular acidosis
- Renal artery stenosis and renovascular hypertension
- Mesangiolipidosis and tubulointerstitial nephritis
Skeletal Anomalies
Skeletal abnormalities in ALGS arise from underlying genetic mutations and the effects of chronic cholestasis. Characteristic facial dysmorphism, present in up to 89% of patients, is a key diagnostic feature and includes deep-set eyes, hypertelorism, a triangular face, and a bulbous nasal tip. These features are often evident in infancy but may become less pronounced in adulthood.[26][27] The most common skeletal manifestation, observed in 30% to 90% of patients, is vertebral anomaly—most notably butterfly vertebrae—resulting from anterior arch fusion defects, typically involving the lower thoracic spine (D6–D9).[1][6] Additional skeletal abnormalities include spina bifida occulta, hemivertebrae, vertebra plana, short ulna, absent 12th rib, and hypoplastic phalanges.[28] Chronic cholestasis further contributes to osteopenia and an increased risk of long-bone fractures.[29]
Ocular Abnormalities
Multiple ocular abnormalities have been described in ALGS, with posterior embryotoxon being the most common finding, reported in 55% to 95% of affected individuals and typically not associated with visual impairment.[30][31] Additional ocular manifestations include peripheral chorioretinal changes and optic nerve drusen.[32]
Vascular Abnormalities
Intracranial vascular anomalies are a recognized feature of ALGS, occurring in 12% to 15% of patients and accounting for an estimated 25% to 50% of noncardiac mortality in children.[33] Clinical presentations range from silent cerebral infarction to fatal intracranial hemorrhage, depending on lesion type and severity. Reported abnormalities include internal carotid artery absence or stenosis, cerebral aneurysms, intracranial hemorrhage, and moyamoya disease.[34]
Extracranial vascular involvement—affecting the celiac, renal, hepatic, and mesenteric arteries, as well as the aorta—has also been reported in both pediatric and adult populations.[35] Other associated features of ALGS include short stature, failure to thrive, immunodeficiency, and recurrent infections. Neurodevelopmental delay, delayed puberty, supernumerary flexion creases, and pancreatic insufficiency have also been reported.
Evaluation
Evaluation of ALGS requires a comprehensive, multidisciplinary approach given its multisystem involvement and marked phenotypic variability. Initial assessment typically integrates clinical features, laboratory evidence of cholestasis, and targeted imaging to evaluate hepatic, cardiac, renal, skeletal, ocular, and vascular manifestations. Genetic testing for pathogenic variants in JAG1 and NOTCH2 is central to confirming the diagnosis, particularly in patients with incomplete clinical features.
Early and systematic evaluation is essential for establishing disease extent, guiding management, and informing prognosis. Most patients present in early infancy with cholestatic jaundice.[16] A smaller group is diagnosed later, either because of symptoms of liver disease or through family screening.
Laboratory Evaluation
The North American and European Societies for Pediatric Gastroenterology, Hepatology, and Nutrition jointly recommend a tiered approach to evaluating cholestatic infants.[14]
- Tier 1: Expedited focused investigations when cholestasis is suspected
- Fractionated bilirubin: Total and conjugated/direct
- Liver enzymes, including gamma-glutamyl transferase, are disproportionately elevated in ALGS, sometimes up to 20 times normal
- Clotting studies
- Complete blood count
- Review of newborn screening results
- Tier 2: Targeted workup in consultation with pediatric gastroenterologist or hepatologist
Imaging Studies
Hepatobiliary evaluation begins with hepatic ultrasonography to assess the liver parenchyma, gallbladder, and biliary tree; Tc-99m technetium-99m diisopropyl iminodiacetic acid hepatobiliary scan hepatobiliary scintigraphy is reserved for selected cases.[38] A small or absent gallbladder, reported in approximately 27.8% of individuals with ALGS, may mimic biliary atresia and should be interpreted with caution in the clinical context.[36] Cardiovascular assessment includes a comprehensive cardiology evaluation with transthoracic echocardiography to identify peripheral pulmonary stenosis, the most common cardiac abnormality, as well as other structural congenital heart defects.[38]
Evaluation of extrahepatic involvement includes anteroposterior and lateral chest radiographs to assess for butterfly vertebrae.[38] Ophthalmologic assessment with slit-lamp examination is recommended to identify posterior embryotoxon and other anterior chamber anomalies, present in approximately 56% to 95% of affected individuals.[38] Renal evaluation should include renal ultrasonography and laboratory assessment of renal function, including blood urea nitrogen, creatinine, and electrolytes, to detect renal dysplasia, cystic disease, or other abnormalities.[38]
Histopathologic Evaluation
Liver biopsy may be performed when the diagnosis of ALGS remains uncertain, though it is often unnecessary when confirmatory genetic testing is available.[14][39] The histologic hallmark is bile duct paucity, defined as a bile duct–to–portal tract ratio less than 0.5; however, this finding may be absent in early infancy and is present in only approximately 65% of biopsies obtained within the first 3 months of life.[36] Immunohistochemical staining using cytokeratin 7 and epithelial membrane antigen (EMA) can improve diagnostic accuracy by distinguishing true interlobular bile ducts from ductular proliferation, with affected individuals showing markedly fewer EMA-positive bile ducts than controls.[40] Early biopsies may instead show ductular proliferation, giant cell hepatitis, or features mimicking biliary atresia, complicating histologic interpretation.[39]
Genetic Testing
Molecular genetic testing is essential for diagnosing ALGS and should be pursued early, particularly in cases that are challenging to diagnose.[39] Testing should include sequencing of JAG1 and NOTCH2, which account for pathogenic variants in approximatley 95% and 5% of affected individuals, respectively.[14] Both sequence analysis and deletion/duplication testing are recommended, as 5% to 7% of JAG1 pathogenic variants involve partial or complete gene deletions. Genetic testing should be considered in children with cholestasis, even in the absence of classic extrahepatic features, and may provide definitive confirmation when clinical and histologic findings are inconclusive.[27][39]
Treatment / Management
ALGS management is primarily supportive and multidisciplinary, focusing on managing cholestasis, pruritus, nutritional deficiencies, and multisystem complications. Liver transplantation remains definitive therapy for end-stage liver disease and refractory complications.
Supportive Medical Therapies
Supportive medical therapy in AlLGS focuses on managing chronic cholestasis and its associated complications to improve symptoms, growth, and quality of life. Treatment is individualized and typically includes interventions for pruritus, nutritional optimization, correction of fat-soluble vitamin deficiencies, and monitoring of liver disease progression. Combination therapy is often required, and the efficacy of these off-label agents is limited.[41][42](A1)
- Pruritus and xanthomas
- Ursodeoxycholic acid (choleretic agent)
- Cholestyramine (bile acid sequestrant)
- Rifampin
- Naltrexone (opioid antagonist)
- Ileal bile acid transporter inhibitors
- Maralixibat (≥3 months)
- Odevixibat (≥12 months)
- Nutritional management
- Optimized nutrition with fat-soluble vitamin replacement (A, D, E, K) for malabsorption
- Nasogastric feeds or a gastrostomy tube may be required to maintain adequate caloric intake for growth [39]
- Hepatocellular carcinoma surveillance
- Serum α-fetoprotein and liver ultrasound every 6 months [39]
(B2)
Surgical Interventions
Surgical biliary diversion may be considered for refractory pruritus in select patients with ALGS and includes partial external biliary diversion, partial internal biliary diversion, or ileal exclusion. These procedures were historically used to interrupt the enterohepatic circulation before the availability of ileal bile acid transporter inhibitors and have been shown to improve pruritus, xanthoma burden, and quality of life in some patients.[5][41] However, surgical approaches have largely been superseded by ileal bile acid transporter inhibitors, which are now preferred as first-line therapy.[42][43](A1)
Liver Transplantation
According to the American Association for the Study of Liver Diseases guidelines, approximately 20% to 30% of patients with ALGS ultimately require liver transplantation. Indications include intractable pruritus, progressive liver synthetic dysfunction, portal hypertension, recurrent fractures or severe osteodystrophy, and growth failure. Notably, advanced synthetic failure, uncontrolled portal hypertension, and chronic hepatic encephalopathy are less common in ALGS compared with other chronic liver diseases.
Although transplantation effectively resolves cholestasis, catch-up growth may be incomplete. Coexisting renal disease necessitates a renal-sparing immunosuppressive strategy to reduce the risk of post-transplant kidney dysfunction. Preoperative vascular imaging is essential given the high prevalence of abdominal arterial anomalies, including celiac trunk stenosis (48%) and overall visceral artery stenosis (58.3%).
Differential Diagnosis
Diseases or conditions that can be mistaken for and must be ruled out during diagnostic evaluation include other causes of neonatal and infantile cholestasis, particularly those presenting with elevated gamma-glutamyl transferase. The differential diagnosis is broad and requires systematic evaluation to distinguish ALGS from both surgical and nonsurgical causes of cholestasis.
The following are included in the differential diagnosis:
- Biliary atresia: Most common cause of infantile cholestasis
- This may closely mimic ALGS.
- Given the potential overlap among liver biopsy, hepatobiliary scintigraphy, and cholangiographic findings, thorough assessment for syndromic features, detailed family history, and confirmatory molecular genetic testing are essential to accurately distinguish between the 2 conditions.
- Progressive familial intrahepatic cholestasis
- α-1 antitrypsin deficiency
- Choledochal cyst
- Cystic fibrosis-related liver disease
- Sclerosing cholangitis
- Congenital hepatic fibrosis
- Metabolic disorders
- Idiopathic neonatal hepatitis
Prognosis
Over 50% of patients with ALGS ultimately require liver transplantation, with outcomes linked to cholestasis severity. In the ChilLDReN cohort, 24% of individuals reached adulthood with their native liver, while 40% developed portal hypertension by age 20.[44] The GALA study's results reported native liver survival of 54% at 10 years and 40% at 18 years, with a total bilirubin less than 5 mg/dL at 6 to 12 months associated with improved long-term outcomes.[45] Overall mortality is approximately 17%, primarily due to cardiac, intracranial, or hepatic complications; 20-year survival approaches 75% overall and is higher among patients not requiring transplant.[44]
Complications
Complications of ALGS involve multiple organ systems. Hepatic manifestations include chronic cholestasis, pruritus, fat-soluble vitamin deficiencies, xanthomas, progressive fibrosis, portal hypertension, and risk of hepatocellular carcinoma. Cardiac and vascular issues such as pulmonary artery stenosis, Tetralogy of Fallot, and cerebrovascular malformations may result in significant morbidity, including intracranial hemorrhage. Renal involvement (eg, renal dysplasia and tubular acidosis), skeletal anomalies (notably butterfly vertebrae and osteopenia), and ocular findings such as posterior embryotoxon are also frequently observed. Advanced disease may be associated with growth failure, delayed puberty, and posttransplant complications.
Deterrence and Patient Education
Patient and family education in ALGS should emphasize the importance of regular multidisciplinary follow-up, adherence to prescribed medications and nutritional regimens, and prompt recognition of warning signs such as worsening jaundice, bleeding, or neurologic changes. Given its autosomal dominant inheritance, genetic counseling is essential. Families should also receive guidance on long-term care planning and strategies to support optimal growth, development, and overall health.
Pearls and Other Issues
Key facts to keep in mind about ALGS include the following:
- Autosomal dominant disorder caused by mutations in JAG1 (most common, ~95%) or NOTCH2, affecting the Notch signaling pathway
- Multisystem disease with highly variable expression, even within the same family
- Classic presentation is infantile cholestasis with direct hyperbilirubinemia
- Histologic hallmark is bile duct paucity (bile duct-to-portal tract ratio <0.5), which may be absent in early infancy
- Can mimic biliary atresia in early infancy
- Cholestatic liver disease with pruritus and xanthomas
- Congenital heart disease, especially peripheral pulmonary artery stenosis
- Butterfly vertebrae on spine imaging
- Posterior embryotoxon on slit-lamp exam
- Characteristic facial features (triangular face, deep-set eyes, prominent forehead, bulbous nasal tip)
- Renal abnormalities such as renal dysplasia or renal tubular acidosis may occur
- Intracranial vascular anomalies increase the risk of hemorrhage
- Increased risk of fat-soluble vitamin deficiencies due to chronic cholestasis
- Genetic testing confirms diagnosis
- Management is supportive; ileal bile acid transporter inhibitors are used for pruritus
- Liver transplantation is required in severe cases
- Mortality is often related to cardiac or intracranial vascular complications
Enhancing Healthcare Team Outcomes
Enhancing outcomes in ALGS requires a coordinated, interprofessional approach centered on effective communication, ethical practice, and patient-focused care. Physicians and advanced practice providers oversee diagnosis, longitudinal surveillance, and multidisciplinary coordination across hepatology, cardiology, nephrology, ophthalmology, nutrition, and genetics. Nurses play a critical role in symptom monitoring, reinforcing adherence to medication and nutritional regimens, and providing ongoing family education.
Pharmacists support safe medication use by adjusting therapies for hepatic or renal dysfunction and minimizing drug interactions and toxicity. Dietitians optimize caloric intake and fat-soluble vitamin supplementation to promote growth and prevent malnutrition. Structured interprofessional communication—including shared care plans, case conferences, and clear documentation—improves care coordination, reduces redundancy, and facilitates timely intervention. Ethical considerations include shared decision-making, respect for family values, and transparent discussions regarding prognosis and liver transplantation options.
References
Turnpenny PD, Ellard S. Alagille syndrome: pathogenesis, diagnosis and management. European journal of human genetics : EJHG. 2012 Mar:20(3):251-7. doi: 10.1038/ejhg.2011.181. Epub 2011 Sep 21 [PubMed PMID: 21934706]
Kohut TJ, Gilbert MA, Loomes KM. Alagille Syndrome: A Focused Review on Clinical Features, Genetics, and Treatment. Seminars in liver disease. 2021 Nov:41(4):525-537. doi: 10.1055/s-0041-1730951. Epub 2021 Jul 2 [PubMed PMID: 34215014]
Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, Qi M, Trask BJ, Kuo WL, Cochran J, Costa T, Pierpont ME, Rand EB, Piccoli DA, Hood L, Spinner NB. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nature genetics. 1997 Jul:16(3):243-51 [PubMed PMID: 9207788]
Level 2 (mid-level) evidenceKrantz ID, Piccoli DA, Spinner NB. Alagille syndrome. Journal of medical genetics. 1997 Feb:34(2):152-7 [PubMed PMID: 9039994]
Squires RH, Ng V, Romero R, Ekong U, Hardikar W, Emre S, Mazariegos GV. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Hepatology (Baltimore, Md.). 2014 Jul:60(1):362-98. doi: 10.1002/hep.27191. Epub [PubMed PMID: 24782219]
Level 1 (high-level) evidencePierpont ME, Brueckner M, Chung WK, Garg V, Lacro RV, McGuire AL, Mital S, Priest JR, Pu WT, Roberts A, Ware SM, Gelb BD, Russell MW, American Heart Association Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Genomic and Precision Medicine. Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association. Circulation. 2018 Nov 20:138(21):e653-e711. doi: 10.1161/CIR.0000000000000606. Epub [PubMed PMID: 30571578]
Vandriel SM, Li LT, She H, Wang JS, Loomes KM, Piccoli DA, Jankowska I, Czubkowski P, Gliwicz-Miedzińska D, D'Antiga L, Nicastro E, Lacaille F, Debray D, Sokal ÉM, Demaret T, Fawaz RL, Nastasio S, Kim KM, Oh SH, Fischler B, Arnell H, Larson-Nath C, Hardikar W, Shankar S, Sundaram SS, Chaidez A, Bulut P, Calvo PL, Kasahara M, Blondet N, Lurz E, Kavallar AM, Gonzales EM, Jacquemin E, Bouligand J, Ebel NH, Feinstein JA, Siew SM, Stormon MO, Karpen SJ, Romero R, Jensen MK, Jaramillo C, Squires JE, Bedoyan SM, Kelly DA, Hartley J, Verkade HJ, Lee WS, Lertudomphonwanit C, Fischer RT, Lin HC, Rock N, Mozer-Glassberg Y, Roberts AJ, Evans HM, Karnsakul W, Nebbia G, Wolters VM, Valentino PL, Bernabeu JQ, Aqul AA, Arikan C, Tamara ML, Busoms CM, Sandahl TD, Indolfi G, Zizzo AN, Zellos A, Quiros-Tejeira RE, Santos-Silva E, Schwarz KB, Brecelj J, Sanchez MC, Cavalieri ML, Tzivinikos C, Wiecek S, Eshun J, Kerkar N, Mujawar Q, Önal Z, Gonçalves C, Garcia J, Alam S, Jimenez-Rivera C, Bujanda L, Thompson RJ, Hansen BE, Spinner NB, Gilbert MA, Kamath BM, Global ALagille Alliance (GALA) Study Group. Phenotypic Divergence of JAG1- and NOTCH2-Associated Alagille Syndrome & Disease-Specific NOTCH2 Variant Classification Guidelines. Liver international : official journal of the International Association for the Study of the Liver. 2025 Sep:45(9):e70251. doi: 10.1111/liv.70251. Epub [PubMed PMID: 40742203]
McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA, Spinner NB. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. American journal of human genetics. 2006 Jul:79(1):169-73 [PubMed PMID: 16773578]
Gilbert MA, Bauer RC, Rajagopalan R, Grochowski CM, Chao G, McEldrew D, Nassur JA, Rand EB, Krock BL, Kamath BM, Krantz ID, Piccoli DA, Loomes KM, Spinner NB. Alagille syndrome mutation update: Comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification. Human mutation. 2019 Dec:40(12):2197-2220. doi: 10.1002/humu.23879. Epub 2019 Aug 26 [PubMed PMID: 31343788]
Level 3 (low-level) evidenceMcCright B, Lozier J, Gridley T. A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development (Cambridge, England). 2002 Feb:129(4):1075-82 [PubMed PMID: 11861489]
Kamath BM, Bason L, Piccoli DA, Krantz ID, Spinner NB. Consequences of JAG1 mutations. Journal of medical genetics. 2003 Dec:40(12):891-5 [PubMed PMID: 14684686]
Ayoub MD, Kamath BM. Alagille Syndrome: Current Understanding of Pathogenesis, and Challenges in Diagnosis and Management. Clinics in liver disease. 2022 Aug:26(3):355-370. doi: 10.1016/j.cld.2022.03.002. Epub 2022 Jun 25 [PubMed PMID: 35868679]
Level 3 (low-level) evidenceHuysentruyt K, Vandriel SM, Roelants M, Piccoli DA, Loomes KM, Rand EB, Ebel NH, Feinstein JA, Jankowska I, Czubkowski P, Gliwicz-Miedzinska D, Gonzales EM, Jacquemin E, Bouligand J, Karpen SJ, Romero R, Lin HC, Fischler B, Arnell H, Li LT, Wang JS, Fawaz R, Nastasio S, Kim KM, Oh SH, D'Antiga L, Nicastro E, Fischer RT, Siew SM, Stormon M, Lertudomphonwanit C, Hardikar W, Shankar S, Squires JE, Sundaram SS, Larson-Nath C, Kelly DA, Hartley J, Bulut P, Jensen MK, Jaramillo C, Roberts AJ, Evans HM, Sokal ÉM, Demaret T, Verkade HJ, Thompson RJ, Hansen BE, Cole TJ, Kamath BM, Debray D, Lacaille F, Brecelj J, El-Koofy NM, Elmonem MA, Lee WS, Sanchez MC, Cavalieri ML, Hajinicolaou C, Schwarz KB, Carvalho E, Rock N, Karnsakul W, Quiros-Tejeira RE, Alam S, Nebbia G, Mozer-Glassberg Y, Valentino PL, Santos-Silva E, Önal Z, Dezsofi-Gottl A, Melere M, Legarda Tamara M, Eshun J, Zellos A, Indolfi G, Rogalidou M, Blondet N, Luigi Calvo P, Beretta M, Zizzo AN, Arikan C, Kasahara M, Kerkar N, Aqul AA, Wolters VM, Borges Pinto R, Quintero Bernabeu J, Garcia J, Wiecek S, Tzivinikos C, Mujawar Q, Jimenez-Rivera C, Molera Busoms C, Gonçalves C, Bujanda L, Global Alagille Alliance (GALA) Study Group. Condition-Specific Growth Charts for Children With Alagille Syndrome. JAMA network open. 2025 Nov 3:8(11):e2545294. doi: 10.1001/jamanetworkopen.2025.45294. Epub 2025 Nov 3 [PubMed PMID: 41284294]
Fawaz R, Baumann U, Ekong U, Fischler B, Hadzic N, Mack CL, McLin VA, Molleston JP, Neimark E, Ng VL, Karpen SJ. Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of pediatric gastroenterology and nutrition. 2017 Jan:64(1):154-168. doi: 10.1097/MPG.0000000000001334. Epub [PubMed PMID: 27429428]
Kamath BM, Baker A, Houwen R, Todorova L, Kerkar N. Systematic Review: The Epidemiology, Natural History, and Burden of Alagille Syndrome. Journal of pediatric gastroenterology and nutrition. 2018 Aug:67(2):148-156. doi: 10.1097/MPG.0000000000001958. Epub [PubMed PMID: 29543694]
Level 1 (high-level) evidenceLykavieris P, Hadchouel M, Chardot C, Bernard O. Outcome of liver disease in children with Alagille syndrome: a study of 163 patients. Gut. 2001 Sep:49(3):431-5 [PubMed PMID: 11511567]
Kamath BM, Munoz PS, Bab N, Baker A, Chen Z, Spinner NB, Piccoli DA. A longitudinal study to identify laboratory predictors of liver disease outcome in Alagille syndrome. Journal of pediatric gastroenterology and nutrition. 2010 May:50(5):526-30. doi: 10.1097/MPG.0b013e3181cea48d. Epub [PubMed PMID: 20421762]
Kahn E. Paucity of interlobular bile ducts. Arteriohepatic dysplasia and nonsyndromic duct paucity. Perspectives in pediatric pathology. 1991:14():168-215 [PubMed PMID: 2038547]
Level 3 (low-level) evidenceMenon J, Shanmugam N, Vij M, Rammohan A, Rela M. Multidisciplinary Management of Alagille Syndrome. Journal of multidisciplinary healthcare. 2022:15():353-364. doi: 10.2147/JMDH.S295441. Epub 2022 Feb 23 [PubMed PMID: 35237041]
McElhinney DB, Krantz ID, Bason L, Piccoli DA, Emerick KM, Spinner NB, Goldmuntz E. Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Circulation. 2002 Nov 12:106(20):2567-74 [PubMed PMID: 12427653]
Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology (Baltimore, Md.). 1999 Mar:29(3):822-9 [PubMed PMID: 10051485]
. Correction to: Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association. Circulation. 2018 Nov 20:138(21):e713. doi: 10.1161/CIR.0000000000000631. Epub [PubMed PMID: 30571587]
Kamath BM, Loomes KM, Piccoli DA. Medical management of Alagille syndrome. Journal of pediatric gastroenterology and nutrition. 2010 Jun:50(6):580-6. doi: 10.1097/MPG.0b013e3181d98ea8. Epub [PubMed PMID: 20479679]
Kamath BM, Podkameni G, Hutchinson AL, Leonard LD, Gerfen J, Krantz ID, Piccoli DA, Spinner NB, Loomes KM, Meyers K. Renal anomalies in Alagille syndrome: a disease-defining feature. American journal of medical genetics. Part A. 2012 Jan:158A(1):85-9. doi: 10.1002/ajmg.a.34369. Epub 2011 Nov 21 [PubMed PMID: 22105858]
Valamparampil JJ, Reddy MS, Shanmugam N, Vij M, Kanagavelu RG, Rela M. Living donor liver transplantation in Alagille syndrome-Single center experience from south Asia. Pediatric transplantation. 2019 Dec:23(8):e13579. doi: 10.1111/petr.13579. Epub 2019 Sep 30 [PubMed PMID: 31571364]
van Duijn C Jr. Toxic and photodynamic effects of vital staining with cresyl blue on bull spermatozoa. Mikroskopie. 1975 Apr:31(1-2):14-22 [PubMed PMID: 51485]
Semenova N, Kamenets E, Annenkova E, Marakhonov A, Gusarova E, Demina N, Guseva D, Anisimova I, Degtyareva A, Taran N, Strokova T, Zakharova E. Clinical Characterization of Alagille Syndrome in Patients with Cholestatic Liver Disease. International journal of molecular sciences. 2023 Jul 21:24(14):. doi: 10.3390/ijms241411758. Epub 2023 Jul 21 [PubMed PMID: 37511516]
D'Amico A, Perillo T, Cuocolo R, Ugga L, Di Dato F, Caranci F, Iorio R. Neuroradiological findings in Alagille syndrome. The British journal of radiology. 2022 Jan 1:95(1129):20201241. doi: 10.1259/bjr.20201241. Epub 2021 Oct 5 [PubMed PMID: 34609904]
Bales CB, Kamath BM, Munoz PS, Nguyen A, Piccoli DA, Spinner NB, Horn D, Shults J, Leonard MB, Grimberg A, Loomes KM. Pathologic lower extremity fractures in children with Alagille syndrome. Journal of pediatric gastroenterology and nutrition. 2010 Jul:51(1):66-70. doi: 10.1097/MPG.0b013e3181cb9629. Epub [PubMed PMID: 20453673]
Deprettere A, Portmann B, Mowat AP. Syndromic paucity of the intrahepatic bile ducts: diagnostic difficulty; severe morbidity throughout early childhood. Journal of pediatric gastroenterology and nutrition. 1987 Nov-Dec:6(6):865-71 [PubMed PMID: 3681572]
Hingorani M, Nischal KK, Davies A, Bentley C, Vivian A, Baker AJ, Mieli-Vergani G, Bird AC, Aclimandos WA. Ocular abnormalities in Alagille syndrome. Ophthalmology. 1999 Feb:106(2):330-7 [PubMed PMID: 9951486]
da Palma MM, Igelman AD, Ku C, Burr A, You JY, Place EM, Wang NK, Oh JK, Branham KE, Zhang X, Ahn J, Gorin MB, Lam BL, Ronquillo CC, Bernstein PS, Nagiel A, Huckfeldt R, Cabrera MT, Kelly JP, Bakall B, Iannaccone A, Hufnagel RB, Zein WM, Koenekoop RK, Birch DG, Yang P, Fahim AT, Pennesi ME. Characterization of the Spectrum of Ophthalmic Changes in Patients With Alagille Syndrome. Investigative ophthalmology & visual science. 2021 Jun 1:62(7):27. doi: 10.1167/iovs.62.7.27. Epub [PubMed PMID: 34185059]
Ayoub MD, Bakhsh AA, Vandriel SM, Keitel V, Kamath BM. Management of adults with Alagille syndrome. Hepatology international. 2023 Oct:17(5):1098-1112. doi: 10.1007/s12072-023-10578-x. Epub 2023 Aug 16 [PubMed PMID: 37584849]
Kamath BM, Spinner NB, Emerick KM, Chudley AE, Booth C, Piccoli DA, Krantz ID. Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality. Circulation. 2004 Mar 23:109(11):1354-8 [PubMed PMID: 14993126]
Kohaut J, Pommier R, Guerin F, Pariente D, Jacquemin E, Martelli H, Branchereau S. Abdominal Arterial Anomalies in Children With Alagille Syndrome: Surgical Aspects and Outcomes of Liver Transplantation. Journal of pediatric gastroenterology and nutrition. 2017 Jun:64(6):888-891. doi: 10.1097/MPG.0000000000001538. Epub [PubMed PMID: 28141679]
Subramaniam P, Knisely A, Portmann B, Qureshi SA, Aclimandos WA, Karani JB, Baker AJ. Diagnosis of Alagille syndrome-25 years of experience at King's College Hospital. Journal of pediatric gastroenterology and nutrition. 2011 Jan:52(1):84-9. doi: 10.1097/MPG.0b013e3181f1572d. Epub [PubMed PMID: 21119543]
Chen Y, Sun M, Teng X. Clinical and genetic analysis in Chinese children with Alagille syndrome. BMC pediatrics. 2022 Nov 29:22(1):688. doi: 10.1186/s12887-022-03750-z. Epub 2022 Nov 29 [PubMed PMID: 36447191]
Mitchell E, Gilbert M, Loomes KM. Alagille Syndrome. Clinics in liver disease. 2018 Nov:22(4):625-641. doi: 10.1016/j.cld.2018.06.001. Epub 2018 Aug 22 [PubMed PMID: 30266153]
Zhou SY, Zhan X, Li SY. Prompt distinction of Alagille syndrome and biliary Atresia in infants: a comparative study. BMC pediatrics. 2025 Jul 9:25(1):543. doi: 10.1186/s12887-025-05896-y. Epub 2025 Jul 9 [PubMed PMID: 40634917]
Level 2 (mid-level) evidenceHerman HK, Abramowsky CR, Caltharp S, Metry D, Cundiff CA, Romero R, Gillespie SE, Shehata BM. Identification of Bile Duct Paucity in Alagille Syndrome: Using CK7 and EMA Immunohistochemistry as a Reliable Panel for Accurate Diagnosis. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society. 2016 Jan-Feb:19(1):47-50. doi: 10.2350/15-05-1628-OA.1. Epub 2015 Sep 14 [PubMed PMID: 26366614]
Gonzales E, Hardikar W, Stormon M, Baker A, Hierro L, Gliwicz D, Lacaille F, Lachaux A, Sturm E, Setchell KDR, Kennedy C, Dorenbaum A, Steinmetz J, Desai NK, Wardle AJ, Garner W, Vig P, Jaecklin T, Sokal EM, Jacquemin E. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet (London, England). 2021 Oct 30:398(10311):1581-1592. doi: 10.1016/S0140-6736(21)01256-3. Epub 2021 Oct 28 [PubMed PMID: 34755627]
Level 1 (high-level) evidenceCheng K, Rosenthal P. Diagnosis and management of Alagille and progressive familial intrahepatic cholestasis. Hepatology communications. 2023 Dec 1:7(12):. doi: 10.1097/HC9.0000000000000314. Epub 2023 Dec 7 [PubMed PMID: 38055640]
Jarasvaraparn C, Rodrigo M, Hartley C, Karnsakul W. Exploring odevixibat's efficacy in alagille syndrome: insights from recent clinical trials and IBAT inhibitor experiences. Expert opinion on pharmacotherapy. 2024 Aug:25(12):1647-1655. doi: 10.1080/14656566.2024.2392873. Epub 2024 Aug 21 [PubMed PMID: 39155775]
Level 3 (low-level) evidenceKamath BM, Ye W, Goodrich NP, Loomes KM, Romero R, Heubi JE, Leung DH, Spinner NB, Piccoli DA, Alonso EM, Guthery SL, Karpen SJ, Mack CL, Molleston JP, Murray KF, Rosenthal P, Squires JE, Teckman J, Wang KS, Thompson R, Magee JC, Sokol RJ, Childhood Liver Disease Research Network (ChiLDReN). Outcomes of Childhood Cholestasis in Alagille Syndrome: Results of a Multicenter Observational Study. Hepatology communications. 2020 Mar:4(3):387-398. doi: 10.1002/hep4.1468. Epub 2020 Jan 22 [PubMed PMID: 33313463]
Level 2 (mid-level) evidenceVandriel SM, Li LT, She H, Wang JS, Gilbert MA, Jankowska I, Czubkowski P, Gliwicz-Miedzińska D, Gonzales EM, Jacquemin E, Bouligand J, Spinner NB, Loomes KM, Piccoli DA, D'Antiga L, Nicastro E, Sokal É, Demaret T, Ebel NH, Feinstein JA, Fawaz R, Nastasio S, Lacaille F, Debray D, Arnell H, Fischler B, Siew S, Stormon M, Karpen SJ, Romero R, Kim KM, Baek WY, Hardikar W, Shankar S, Roberts AJ, Evans HM, Jensen MK, Kavan M, Sundaram SS, Chaidez A, Karthikeyan P, Sanchez MC, Cavalieri ML, Verkade HJ, Lee WS, Squires JE, Hajinicolaou C, Lertudomphonwanit C, Fischer RT, Larson-Nath C, Mozer-Glassberg Y, Arikan C, Lin HC, Bernabeu JQ, Alam S, Kelly DA, Carvalho E, Ferreira CT, Indolfi G, Quiros-Tejeira RE, Bulut P, Calvo PL, Önal Z, Valentino PL, Desai DM, Eshun J, Rogalidou M, Dezsőfi A, Wiecek S, Nebbia G, Pinto RB, Wolters VM, Tamara ML, Zizzo AN, Garcia J, Schwarz K, Beretta M, Sandahl TD, Jimenez-Rivera C, Kerkar N, Brecelj J, Mujawar Q, Rock N, Busoms CM, Karnsakul W, Lurz E, Santos-Silva E, Blondet N, Bujanda L, Shah U, Thompson RJ, Hansen BE, Kamath BM, Global ALagille Alliance (GALA) Study Group. Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study. Hepatology (Baltimore, Md.). 2023 Feb 1:77(2):512-529. doi: 10.1002/hep.32761. Epub 2022 Oct 13 [PubMed PMID: 36036223]